COVID-19 future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Line 43: | Line 43: | ||
|Conjugated subunit | |Conjugated subunit | ||
| | | | ||
* Spike protein S1 | |||
* Receptor binding domain | |||
* Nucleocapsid | |||
* Membrane protein | |||
* Envelope protein | |||
* Delta Inulin Adjuvant | |||
| | | | ||
| | | |
Revision as of 13:23, 17 March 2020
COVID-19 Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
COVID-19 future or investigational therapies On the Web |
American Roentgen Ray Society Images of COVID-19 future or investigational therapies |
Risk calculators and risk factors for COVID-19 future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
Immune Targets
- The B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins are currently under investigation as immune targets for development of vaccine.
- Phylogenetic similarity between SARS-CoV and COVID-19 at the level of structural proteins S, E, M, and N is providing guidance for development of a possible vaccine.
Prior Work
The following table depicts major vaccine products that have been developed against SARS-CoV and MERS-CoV:
Vaccine Base | Antigen | Clinical Testing | Pros | Cons |
---|---|---|---|---|
DNA | Spike protein S1 | Phase I, II
(NCT03721718) |
|
|
Viral Vector | Spike protein S1; Chimpanzee adenovirus vector, Modified Vaccinia Ankara | |||
Conjugated subunit |
|
|||
Virion | ||||
Inactivated | ||||
Live attenuated |